Please log in
You must be logged in to send the contact request.
Manage stand orders
Select Option
Green Cross Medical Science Corp.
107, Ihyeon-ro 30beon-gli, Giheung-gu,
16954
Yongin-si, Gyeonggi-do
Korea, Republic
Korea, Republic
Telephone +82 31 2601926
Fax +82 31 2609416
gcms.overseas@greencross.com
http://www.greencrossms.com/eng/main.do?lang=EN
Fax +82 31 2609416
gcms.overseas@greencross.com
http://www.greencrossms.com/eng/main.do?lang=EN
Submit your contact details
Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
Contact
Scott Chang
Regional Manager - Middle East, India
Global Business
Global Business
Yuki Im
Regional Manager - Europe, Japan
Global Business
Global Business
Sung Hyun Yoon
Regional Manager - Asia, China
Global Business
Global Business
Julie Choi
Regional Manager - LATAM, Africa
Global Business
Global Business
Visit us
17.11.2020
Topic
all-day
Webinar for COVID-19 product
1. COVID-19 Ag rapid kit
2. COVID-19 Ab rapid kit
3. COVID-19 RT-PCR
Have you ever heard about GENEDIA W COVID-19 kit?
GCMS can provide you total solution of COVID-19.
If you request to make matchmaking for 'Jung wook Kim' working at GCMS, we will suggest special offer to you in person on the meeting.
Please have interest in our company and product
0r if you would like to meet us, please follow below mail
gcms.overseas@gccorp.com
2. COVID-19 Ab rapid kit
3. COVID-19 RT-PCR
Have you ever heard about GENEDIA W COVID-19 kit?
GCMS can provide you total solution of COVID-19.
If you request to make matchmaking for 'Jung wook Kim' working at GCMS, we will suggest special offer to you in person on the meeting.
Please have interest in our company and product
0r if you would like to meet us, please follow below mail
gcms.overseas@gccorp.com
Our range of products
Product categories
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.01 Immuno assay testing
Immuno assay testing
- 03 Diagnostic tests
- 03.02 Immunochemistry testing, immunology testing
- 03.02.02 Diagnostic rapid tests
Diagnostic rapid tests
- 03 Diagnostic tests
- 03.05 Infectious immunology testing
- 03.05.03 Other infectious immunology testing
Other infectious immunology testing
Our products
Product category: Diagnostic rapid tests, Immuno assay testing, Other infectious immunology testing
GENEDIA W ONE COVID-19 IgM/IgG
The principle of GENEDIA W ONE COVID-19 IgM/IgG Antibody Test is an antibody-capture immunochromatographic assay for the simultaneous detection and differentiation of IgM & IgG antibodies to COVID-19 virus in human serum, plasma, and/or whole blood samples.
COVID-19 virus-specific antigens are conjugated to a colloidal gold and deposited on the conjugate pad.
When the sample is added the gold-antigen conjugate is rehydrated and the COVID-19 IgM and/or IgG antibodies, if any in the sample, will interact with the gold conjugated antigen.
The immunocomplex will migrate towards the test window until the test zone where they will be captured by the relevant anti-human IgM and/or antihuman IgG, forming a visible line, indicating positive results.
If COVID-19 antibodies are absent in the sample, no line will appear in the test lines, indicating a negative result.
To serve as an internal process control, a control line should always appear at Control Zone after the test is completed.
Absence of a control line in the Control Zone is an indication of an invalid result
COVID-19 virus-specific antigens are conjugated to a colloidal gold and deposited on the conjugate pad.
When the sample is added the gold-antigen conjugate is rehydrated and the COVID-19 IgM and/or IgG antibodies, if any in the sample, will interact with the gold conjugated antigen.
The immunocomplex will migrate towards the test window until the test zone where they will be captured by the relevant anti-human IgM and/or antihuman IgG, forming a visible line, indicating positive results.
If COVID-19 antibodies are absent in the sample, no line will appear in the test lines, indicating a negative result.
To serve as an internal process control, a control line should always appear at Control Zone after the test is completed.
Absence of a control line in the Control Zone is an indication of an invalid result
Product category: Immuno assay testing, Diagnostic rapid tests, Other infectious immunology testing
GENEDIA W COVID-19 Ag
The principle of GENEDIA W COVID-19 Ag Antigen Test is an antigen-capture immunochromatographic assay for the simultaneous detection Antigen to COVID-19 virus present in human nasopharyngeal swab and sputum.
Antibody of COVID-19 are conjugated to a colloidal gold and deposited on the conjugate pad.
When the sample is added the gold-antibody conjugate is rehydrated and the COVID-19 antigen, if any in the sample, will interact with the gold conjugated antibody.
The immunocomplex will migrate towards the test window until the test zone where they will be captured by the relevant antigen-human , forming a visible line, indicating positive results.
If COVID-19 antigen are absent in the sample, no line will appear in the test lines, indicating a negative result.
Control line should always appear at Control Zone after the test is completed.
Absence of a control line in the Control Zone is an indication of an invalid result.
Antibody of COVID-19 are conjugated to a colloidal gold and deposited on the conjugate pad.
When the sample is added the gold-antibody conjugate is rehydrated and the COVID-19 antigen, if any in the sample, will interact with the gold conjugated antibody.
The immunocomplex will migrate towards the test window until the test zone where they will be captured by the relevant antigen-human , forming a visible line, indicating positive results.
If COVID-19 antigen are absent in the sample, no line will appear in the test lines, indicating a negative result.
Control line should always appear at Control Zone after the test is completed.
Absence of a control line in the Control Zone is an indication of an invalid result.
Product category: Immuno assay testing, Diagnostic rapid tests, Other infectious immunology testing
GENEDIA Quantum COVID-19 Ag & GENEDIA Quantum FR101
The GENEDIA Quantum COVID-19 Ag is a fluorescence immunoassay kit for rapid and qualitative determination of SARS-CoV-2 infection from nasopharyngeal swab and sputum specimens.
Test kit contains a membrane strip, which is immobilized with the anti-SARS-CoV-2 monoclonal antibody on the test line (T) and Goat-anti mouse IgG on the control line (C) respectively.
And the strip is assembled in the test device. When the sample and the extraction solution are applied to the sample well, the sample is moved to the quantum dot bead conjugated pad and reacts with anti-SARS-CoV-2 monoclonal antibody-coupled quantum dot bead conjugate followed by reaction with anti-SARS-CoV-2 monoclonal antibody immobilized in the test line.
When the sample contains SARS-CoV-2 antigens, an invisible fluorescence line appears in the test region on the membrane.
The solution continues to migrate to encounter a control reagent, thereby producing another band in the control region.
The GENEDIA Quantum FR101 will scan the test device and measure the fluorescent signal.
The GENEDIA Quantum FR101 will display the test results (Positive, Negative, or Invalid) on the screen.
The GENEDIA Quantum COVID-19 Ag is very useful to directly detect SARS-CoV-2 antigens from nasopharyngeal swab and sputum samples
---------------------------------------------------------------------------------------------------------------------------------------
GENEDIA Quantum FR101 is a fluorescence analyzer for analyzing the fluorescence of the GENEDIA Quantum test kit based on immunoassay technology in which antigen-antibody and fluorescent substances are combined.
The GENEDIA Quantum FR101 is a device that detects fluorescence through a camera by irradiating a light-emitting diode on the surface that causes fluorescence on the GENEDIA Quantum test kit to collect the excited fluorescence.
The camera image is calculated quantitatively through an algorithm and the density is displayed on the GENEDIA QUANTUM FR101 screen.
Test kit contains a membrane strip, which is immobilized with the anti-SARS-CoV-2 monoclonal antibody on the test line (T) and Goat-anti mouse IgG on the control line (C) respectively.
And the strip is assembled in the test device. When the sample and the extraction solution are applied to the sample well, the sample is moved to the quantum dot bead conjugated pad and reacts with anti-SARS-CoV-2 monoclonal antibody-coupled quantum dot bead conjugate followed by reaction with anti-SARS-CoV-2 monoclonal antibody immobilized in the test line.
When the sample contains SARS-CoV-2 antigens, an invisible fluorescence line appears in the test region on the membrane.
The solution continues to migrate to encounter a control reagent, thereby producing another band in the control region.
The GENEDIA Quantum FR101 will scan the test device and measure the fluorescent signal.
The GENEDIA Quantum FR101 will display the test results (Positive, Negative, or Invalid) on the screen.
The GENEDIA Quantum COVID-19 Ag is very useful to directly detect SARS-CoV-2 antigens from nasopharyngeal swab and sputum samples
---------------------------------------------------------------------------------------------------------------------------------------
GENEDIA Quantum FR101 is a fluorescence analyzer for analyzing the fluorescence of the GENEDIA Quantum test kit based on immunoassay technology in which antigen-antibody and fluorescent substances are combined.
The GENEDIA Quantum FR101 is a device that detects fluorescence through a camera by irradiating a light-emitting diode on the surface that causes fluorescence on the GENEDIA Quantum test kit to collect the excited fluorescence.
The camera image is calculated quantitatively through an algorithm and the density is displayed on the GENEDIA QUANTUM FR101 screen.
Product category: Immuno assay testing, Diagnostic rapid tests, Other infectious immunology testing
GENEDIA W COVID-19 Real-Time RT-PCR
GENEDIA W COVID-19 Real-Time RT PCR kit reagent is a test to qualitatively extract SARS-CoV-2 virus RNA from substances of human respiratory organs (Nasopharyngeal, Oropharyngeal swab, Sputum, Bronchoalveolar lavage) on a real-time basis. After disease was confirmed in China on December, 2019, causal virus turned out to be similar with SARS-CoV that it was named as SARS-CoV-2 as a new virus. Since January, 2020, it went beyond China spreading all over the world and became a global pan- demic by WHO on March. Symptoms of Corona Virus-19 include fever, dry cough, or other minor respiratory symptoms that are similar with other respiratory diseases that it is difficult to identify patients only with early symptoms. If symptoms become worse leading to serious respiratory symptoms such as difficulty in breathing, decrease of oxygen saturation, or pneumonia, oxygen treatment or mechanical ventilation might be required.
Product category: Immuno assay testing, Diagnostic rapid tests, Other infectious immunology testing
GENEDIAMulti Influenza Ag Rapid Test Kit
The GENEDIA Multi-Influenza Ag Rapid Test Kit is an in vitro diagnostic single-use test and for the rapid qualitative determination of Influenza A, B and it can identify of Influenza A to subtype H1N1 and H3N2 in nasopharyngeal swabbed sample. This assay is designed for professional personnel in laboratory and at point-of-care as an aid in screening patients suspected of being infected and asymptomatic patients.
Influenza, commonly known as “the flu”, is an acute respiratory disease caused by infection with in- fluenza type A and influenza type B viruses. All influenza A viruses are sub-grouped on the basis of their surface haemagglutinin (H) and neuraminidase (N) glycoproteins, of which there are 16 known types of H and 9 types of N. The current subtypes of influenza A viruses circulating most widely among humans are A (H1N1) and A (H3N2).
The GENEDIA Multi-Influenza Ag Rapid Test Kit is a rapid and simple assay for the qualitative determination of influenza A and B. Additionally, the test divided determine of influenza A/H1 and A/H3 in nasopharyngeal swabbed sample.
The GENEDIA Multi-Influenza Ag Rapid Test Kit device is made up of two test strips and a plastic cassette. The test strips were composed of a nitrocellulose membrane, a dried gold conjugate pad, an absorbent pad, and sample pads. The nitrocellulose membrane is immobilized with monoclonal anti influenza H1 antibody, anti-influenza H3 antibody, anti-influenza A antibody and anti-influenza B an-tibody on the test line. The assay does not require any laboratory equipment and the kit can be stored at room temperature for extended periods of time.
Influenza, commonly known as “the flu”, is an acute respiratory disease caused by infection with in- fluenza type A and influenza type B viruses. All influenza A viruses are sub-grouped on the basis of their surface haemagglutinin (H) and neuraminidase (N) glycoproteins, of which there are 16 known types of H and 9 types of N. The current subtypes of influenza A viruses circulating most widely among humans are A (H1N1) and A (H3N2).
The GENEDIA Multi-Influenza Ag Rapid Test Kit is a rapid and simple assay for the qualitative determination of influenza A and B. Additionally, the test divided determine of influenza A/H1 and A/H3 in nasopharyngeal swabbed sample.
The GENEDIA Multi-Influenza Ag Rapid Test Kit device is made up of two test strips and a plastic cassette. The test strips were composed of a nitrocellulose membrane, a dried gold conjugate pad, an absorbent pad, and sample pads. The nitrocellulose membrane is immobilized with monoclonal anti influenza H1 antibody, anti-influenza H3 antibody, anti-influenza A antibody and anti-influenza B an-tibody on the test line. The assay does not require any laboratory equipment and the kit can be stored at room temperature for extended periods of time.
Product category: Diagnostic rapid tests
GREENCARE LIPID
The GREENCARE LIPID is an in vitro diagnostic medical device for measurements of total cholesterol, triglycerides, HDL cholesterol in whole blood by colorimetric assay with enzyme reaction. And the GREENCARE LIPID is an in vitro diagnostic medical device that can diagnose diabetes by measuring blood glucose through electrochemical reactions.
Product category: Diagnostic rapid tests
GREENCARE A1c
GREENCARE A1c is a device for measuring hemoglobin A1c concentration in the blood by analyzing the intensity of light reflected from the measurement area, and it is an in vitro diagnostic device that is used professionally in hospitals and clinical laboratories.
After opening the analyzer cover, insert the cassette of the GREENCARE A1c Hemoglobin A1c Test Kit into the analyzer holder, collect blood from the blood sampling area at the end of the reagent pack, and insert the reagent pack into the cassette. When the reagent pack is inserted into the cassette, the sealed part on both sides of the reagent pack is released. The user closes the cover of the analyzer, the analyzer automatically starts the measurement operation. The result is dis- played on the screen when the measurement is completed.
After opening the analyzer cover, insert the cassette of the GREENCARE A1c Hemoglobin A1c Test Kit into the analyzer holder, collect blood from the blood sampling area at the end of the reagent pack, and insert the reagent pack into the cassette. When the reagent pack is inserted into the cassette, the sealed part on both sides of the reagent pack is released. The user closes the cover of the analyzer, the analyzer automatically starts the measurement operation. The result is dis- played on the screen when the measurement is completed.
Product category: Diagnostic rapid tests
CERA-CHEK™ 1Code PRIME Blood Glucose Monitoring System
The CERA-CHEK™ 1Code PRIME is superior in accuracy, precision and portability. Moreover, the CERA-CHEK™ 1Code PRIME offers great convenience to the user by skipping the procedure of ‘Coding the meter’. This allows for better management of your diabetes and periodic blood glucose testing.
The CERA-CHEK™ 1Code PRIME Blood Glucose Monitoring System is intended to help people manage their diabetes with measuring their glucose level with fresh capillary whole blood the fingertip, the palm, the forearm, the upper arm, the thigh, or the calf for self-testing. It also provides professional healthcare personnel with the helpful information with measuring glucose concentration in fresh capillary whole blood.
The test is based on the measurement of an electrical current generated by the reaction of glucose with the reagent of the test strip. The test meter measures the current and displays the corresponding blood glucose level. The strength of the current produced by the reaction depends on the amount of glucose in the blood sample.
The CERA-CHEK™ 1Code PRIME Blood Glucose Monitoring System is intended to help people manage their diabetes with measuring their glucose level with fresh capillary whole blood the fingertip, the palm, the forearm, the upper arm, the thigh, or the calf for self-testing. It also provides professional healthcare personnel with the helpful information with measuring glucose concentration in fresh capillary whole blood.
The test is based on the measurement of an electrical current generated by the reaction of glucose with the reagent of the test strip. The test meter measures the current and displays the corresponding blood glucose level. The strength of the current produced by the reaction depends on the amount of glucose in the blood sample.
Company news
Date
Topic
Download
Nov 30, 2020
GC MS to increase export of Covid-19 diagnostic kit
GC MS said that it has obtained an export approval for GENEDIA W COVID-19 Ag, a point of care testing (POCT) antigen diagnosis kit, from the Ministry of Food and Drug Safety.
GC MS has received export approval for GENEDIA W COVID-19 Ag, a Covid-19 diagnostic kit, from the Ministry of Drug and Safety. (GC MS)
The device is an antigen-diagnosing kit that detects Covid-19 infection on-site within 10 minutes by using a nasopharyngeal and sputum sample to visually check Covid-19 patients in their early stages without additional equipment.
“The demand for such diagnostic kits is increasing in developing countries where medical infrastructure is weak and there are few expensive gene amplification (PCR) equipment,” the company said. “
With the approval, the company has five Covid-19 diagnostic kits, including two antibody diagnostic kits and two molecular diagnostic kits, approved for export.
The company expects that it will be able to respond to different demands by strengthening its lineup efficiently.
“The newest product is likely to be in demand as a field diagnosis method required before and after administering a Covid-19 vaccine,” GC MS CEO Ahn Eun-eok said. “In the future, we plan to build an integrated diagnostic platform related to Covid-19 by adding fluorescent immunity products.”
GC MS has received export approval for GENEDIA W COVID-19 Ag, a Covid-19 diagnostic kit, from the Ministry of Drug and Safety. (GC MS)
The device is an antigen-diagnosing kit that detects Covid-19 infection on-site within 10 minutes by using a nasopharyngeal and sputum sample to visually check Covid-19 patients in their early stages without additional equipment.
“The demand for such diagnostic kits is increasing in developing countries where medical infrastructure is weak and there are few expensive gene amplification (PCR) equipment,” the company said. “
With the approval, the company has five Covid-19 diagnostic kits, including two antibody diagnostic kits and two molecular diagnostic kits, approved for export.
The company expects that it will be able to respond to different demands by strengthening its lineup efficiently.
“The newest product is likely to be in demand as a field diagnosis method required before and after administering a Covid-19 vaccine,” GC MS CEO Ahn Eun-eok said. “In the future, we plan to build an integrated diagnostic platform related to Covid-19 by adding fluorescent immunity products.”
About us
Company details
GCMS is one of the first-generation service providers of vitro diagnosis, which we used import in the 1960s and 70s. Our company dates back to 1972 when GCMS jumped into the in vitro diagnosis business by setting up a dedicated organization and has achieved phenomenal growth. GC Pharma spun off its Diagnosis Business Division to set up an independent corporation dedicated to diagnostic reagent in 2004. GC Pharma has made remarkable contributions in leading the growth and development of our domestic diagnosis industry for the past four decades.
Since 1972 when the first blood grouping reagent was introduced to market, our company has developed and distributed a variety of sophisticated reagents to medical institutions at home and abroad. These include infectious diseases (HIV, HBV, HCV etc.) test reagents, and tumor marker and parasitological test reagents which require very advanced technologies.
In addition, the company established a cooperative marketing partnership in 1978 with Boehringer Ingelheim, a world class diagnostic reagent company based in Germany, and co-founded Green Cross Boehringer Ingelheim Co., Ltd., a cooperative joint venture in 1992. This joint venture enabled the company to achieve impressive growth in the major areas of in vitro diagnosis, including clinical immunity, clinical chemistry, and diabetes diagnosis. The company also developed and introduced GENEDIA HIV 1/2 ELISA, an HIV/AIDS diagnostic reagent, for the first time in Korea in 1987 through long-term consistent R&D efforts as part of our commitment to promoting public health.
GCMS was founded in 2004 as an independent corporation in a bid to diversity our business portfolio to medication equipment, and devices and other supplies in addition to the in vitro diagnosis business.
GCMS has achieved annual growth of 20% or more in its relevant market, and more recently pushed ahead with upgrading diagnostic reagents based on real-time molecular reagents and specific recombination antibody forming technology.
As such, GC Pharma has made consistent efforts to develop and introduce market-oriented products under the motto “Open R&D/Innovation” while seeking to solidify its image as a ‘global player’ as we boost our effort to develop products targeting international markets around the world, including the US, Russia, Europe, Africa, Middle East, and India.
Since 1972 when the first blood grouping reagent was introduced to market, our company has developed and distributed a variety of sophisticated reagents to medical institutions at home and abroad. These include infectious diseases (HIV, HBV, HCV etc.) test reagents, and tumor marker and parasitological test reagents which require very advanced technologies.
In addition, the company established a cooperative marketing partnership in 1978 with Boehringer Ingelheim, a world class diagnostic reagent company based in Germany, and co-founded Green Cross Boehringer Ingelheim Co., Ltd., a cooperative joint venture in 1992. This joint venture enabled the company to achieve impressive growth in the major areas of in vitro diagnosis, including clinical immunity, clinical chemistry, and diabetes diagnosis. The company also developed and introduced GENEDIA HIV 1/2 ELISA, an HIV/AIDS diagnostic reagent, for the first time in Korea in 1987 through long-term consistent R&D efforts as part of our commitment to promoting public health.
GCMS was founded in 2004 as an independent corporation in a bid to diversity our business portfolio to medication equipment, and devices and other supplies in addition to the in vitro diagnosis business.
GCMS has achieved annual growth of 20% or more in its relevant market, and more recently pushed ahead with upgrading diagnostic reagents based on real-time molecular reagents and specific recombination antibody forming technology.
As such, GC Pharma has made consistent efforts to develop and introduce market-oriented products under the motto “Open R&D/Innovation” while seeking to solidify its image as a ‘global player’ as we boost our effort to develop products targeting international markets around the world, including the US, Russia, Europe, Africa, Middle East, and India.